Talk:Allergan

FML Forte (0.25%) OPHTH SUSP 5ML
I have found that the FML Forte eye drop used to used to treat eye PRK and Lasik post operative side affects is at least 10 drops short on the first two bottles that I purchased from Allergan Pharmaceuticals. It is $250.00 U.S. dollars per bottle. They use the metric conversion table to fill their bottles which their Quality Assurance Section stated was 15 drops per ML. It is actually suppose to be 15.4 drops per ML using the metric table. The U.S. conversion table is 20 drops per ML. If you call their Quality Assurance Section they will say they put extra drops in each bottle. They will of course deny that their bottles are short any drops. PRK and Lasik is a very popular eye corrective surgery in the United States. Allergan Stock is $223.00 per share. — Preceding unsigned comment added by 75.71.10.154 (talk) 15:09, 26 April 2016 (UTC)

Interesting, and quite factual analysis that should be further pursued.--Wikipietime (talk) 15:32, 9 September 2017 (UTC)

Proposed merge with Naurex
stub, was bought by Allergan. Natureium (talk) 20:45, 26 January 2017 (UTC)

Intellectual property and patent transfer to St. Regis Mohawk Reservation
St. Regis Mohawk Reservation has come online for protection of ip.

Casinos Aren’t Enough as Native Tribe Makes Deal on Drug Patents

https://www.bloomberg.com/news/articles/2017-09-09/casinos-aren-t-enough-as-native-tribe-makes-deal-on-drug-patents

--Wikipietime (talk) 15:30, 9 September 2017 (UTC)

Edit request to add sources to "Key products" section
On behalf of Allergan, and as part of my work at Beutler Ink, I am looking to make some updates and improvements to this Wikipedia article. I'd like to start with a very straightforward request. Currently, the "Key products" section is almost entirely unsourced. There are two inline citations in the section, both of which direct readers to the Allergan website, and I think we can all agree this is not ideal. I've found sources to verify connections between Allergan and each of the products currently listed in this section. I believe they are appropriate for Wikipedia, and I've not made other major content changes. I'm merely attempting to improve the article's integrity by adding sourcing. Below, I offer a rendering of an updated "Key products" section and markup for editor review:

• Actonel (risedronic acid) for the treatment or prevention osteoporosis, and for Paget's disease of bone treatment

• Acuvail (ketorolac ophthalmic solution) for the treatment of pain and inflammation following cataract surgery

• Aczone (dapsone gel) for acne

• Alphagan P (brimonidine ophthalmic solution) for glaucoma

• Androderm CIII (testosterone transdermal system) for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone

• Asacol HD (mesalamine extended release) for moderately active ulcerative colitis

• Atelvia (risedronic acid delayed release) for the treatment of osteoporosis in postmenopausal women

• Avycaz (ceftazidime/avibactam) for complicated intra-abdominal infections (in combination with metronidazole)

• Botox (onabotulinumtoxinA) for various spasms and dystonias

• Botox Cosmetic/Vistabel (onabotulinumtoxinA), an anti-wrinkle cosmetic drug derived from Botox

• Bystolic (nebivolol) for hypertension

• Combigan (brimonidine/timolol) for glaucoma

• Crinone (progesterone gel) for progesterone supplementation or replacement as part of an assisted reproductive technology (ART) treatment for infertile women with progesterone deficiency

• Dalvance (dalbavancin) for acute bacterial skin and skin structure infections (ABSSSI)

• Delzicol (mesalamine extended release) for mildly-to-moderately active ulcerative colitis

• Doryx (doxycycline hyclate extended release), a tetracycline-class antimicrobial

• Enablex (darifenacin extended release) for overactive bladder

• Estrace (estradiol vaginal cream) for vulvar and vaginal atrophy due to menopause

• Fetzima (levomilnacipran extended release) for major depressive disorder

• Gelnique (oxybutynin gel) for overactive bladder

• Juvéderm injectable gel (cross-linked hyaluronic acid), a dermal filler

• Kybella (deoxycholic acid injection) for double chin

• Lastacaft (alcaftadine ophthalmic solution) for the prevention of itching associated with eye allergies

• Latisse (bimatoprost ophthalmic solution) for hypotrichosis of the eyelashes

• Liletta (levonorgestrel-releasing intrauterine system) for contraception

• Linzess (linaclotide) for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation—co-marketed with Ironwood Pharmaceuticals

• Lo Loestrin Fe (norethisterone and ethinylestradiol; ethinylestradiol; ferrous fumarate) for contraception

• Lumigan (bimatoprost ophthalmic solution) for glaucoma

• Namenda (memantine) for moderate-to-severe dementia of the Alzheimer's type

• Namenda XR (memantine extended release) for moderate-to-severe Alzheimer's disease

• Namzaric (memantine extended release/donepezil) for moderate-to severe-Alzheimer's disease in patients who are currently taking and can continue to take certain doses of both Namenda or Namenda XR (see above) and donepezil

• Natrelle breast implants (silicone and saline)

• Optive (carboxymethyl cellulose eye drops) - prescribed for patients who have undergone LASIK to prevent dryness of the eyes

• Ozurdex (dexamethasone intravitreal implant) for branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO)

• Orbera system—an intragastric balloon, inserted endoscopically; designed to assist weight loss by partially filling the stomach and inducing satiety for overweight patients with a body mass index (BMI) of 27 or greater

• Rapaflo (silodosin) for benign prostatic hyperplasia

• Restasis (ciclosporin ophthalmic emulsion) for dry eye syndrome

• Saphris (asenapine sublingual tablets) for schizophrenia and bipolar I disorder

• Skinmedica for facial lines

• Tazorac (tazarotene) for acne and psoriasis

• Teflaro (ceftaroline fosamil) for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI)

• Viberzi (eluxadoline) for diarrhea-predominant irritable bowel syndrome (IBS-D)

• Viibryd (vilazodone) for major depressive disorder

• Zenpep (pancrelipase) for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, or other conditions.

• Actonel (risedronic acid) for the treatment or prevention osteoporosis, and for Paget's disease of bone treatment

•  Acuvail (ketorolac ophthalmic solution) for the treatment of pain and inflammation following cataract surgery

•  Aczone (dapsone gel) for acne

•  Alphagan P (brimonidine ophthalmic solution) for glaucoma

•  Androderm CIII (testosterone transdermal system) for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone

•  Asacol HD (mesalamine extended release) for moderately active ulcerative colitis

•  Atelvia (risedronic acid delayed release) for the treatment of osteoporosis in postmenopausal women

•  Avycaz (ceftazidime/avibactam) for complicated intra-abdominal infections (in combination with metronidazole)

•  Botox (onabotulinumtoxinA) for various spasms and dystonias

•  Botox Cosmetic/Vistabel (onabotulinumtoxinA), an anti-wrinkle cosmetic drug derived from Botox

•  Bystolic (nebivolol) for hypertension

•  Combigan (brimonidine/timolol) for glaucoma

•  Crinone (progesterone gel) for progesterone supplementation or replacement as part of an assisted reproductive technology (ART) treatment for infertile women with progesterone deficiency

•  Dalvance (dalbavancin) for acute bacterial skin and skin structure infections (ABSSSI)

•  Delzicol (mesalamine extended release) for mildly-to-moderately active ulcerative colitis

•  Doryx (doxycycline hyclate extended release), a tetracycline-class antimicrobial

•  Enablex (darifenacin extended release) for overactive bladder

•  Estrace (estradiol vaginal cream) for vulvar and vaginal atrophy due to menopause

•  Fetzima (levomilnacipran extended release) for major depressive disorder

•  Gelnique (oxybutynin gel) for overactive bladder

•  Juvéderm injectable gel (cross-linked hyaluronic acid), a dermal filler

•  Kybella (deoxycholic acid injection) for double chin

•  Lastacaft (alcaftadine ophthalmic solution) for the prevention of itching associated with eye allergies

•  Latisse (bimatoprost ophthalmic solution) for hypotrichosis of the eyelashes

•  Liletta (levonorgestrel-releasing intrauterine system) for contraception

•  Linzess (linaclotide) for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation—co-marketed with Ironwood Pharmaceuticals

•  Lo Loestrin Fe (norethisterone and ethinylestradiol; ethinylestradiol; ferrous fumarate) for contraception

•  Lumigan (bimatoprost ophthalmic solution) for glaucoma

•  Namenda (memantine) for moderate-to-severe dementia of the Alzheimer's type

•  Namenda XR (memantine extended release) for moderate-to-severe Alzheimer's disease

•  Namzaric (memantine extended release/donepezil) for moderate-to severe-Alzheimer's disease in patients who are currently taking and can continue to take certain doses of both Namenda or Namenda XR (see above) and donepezil

•  Natrelle breast implants (silicone and saline)

•  Optive (carboxymethyl cellulose eye drops) - prescribed for patients who have undergone LASIK to prevent dryness of the eyes

•  Ozurdex (dexamethasone intravitreal implant) for branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO)

•  Orbera system—an intragastric balloon, inserted endoscopically; designed to assist weight loss by partially filling the stomach and inducing satiety for overweight patients with a body mass index (BMI) of 27 or greater

•  Rapaflo (silodosin) for benign prostatic hyperplasia

•  Restasis (ciclosporin ophthalmic emulsion) for dry eye syndrome

•  Saphris (asenapine sublingual tablets) for schizophrenia and bipolar I disorder

•  Skinmedica for facial lines

•  Tazorac (tazarotene) for acne and psoriasis

•  Teflaro (ceftaroline fosamil) for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI)

•  Viberzi (eluxadoline) for diarrhea-predominant irritable bowel syndrome (IBS-D)

•  Viibryd (vilazodone) for major depressive disorder

•  Zenpep (pancrelipase) for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, or other conditions.

I'm seeking a volunteer to review the proposed markup and copy over appropriately. Happy to answer any questions here or on my user talk page. Thanks! Inkian Jason (talk) 20:16, 12 January 2018 (UTC)


 * I just removed the section, per WP:NOTCATALOG. The section above would still violate that policy.  Jytdog (talk) 23:39, 12 January 2018 (UTC)
 * Thanks for reviewing this request. I would think an overview of the company's products would be helpful, and my goal here was merely to source unsourced content. While I don't have any problem with your edit to the article, I am curious, would an overview of the company's products in another format be helpful? Inkian Jason (talk) 21:42, 16 January 2018 (UTC)
 * nope, per WP:NOTCATALOG. Jytdog (talk) 00:12, 17 January 2018 (UTC)

I realized I didn't follow up here, apologies for that. While a listing of products is understandably not appropriate, I assume the article should mention something about the products in non-listing, prose form. I'm working on a draft that will do this and will work to ensure it meets guidelines. For now, a short mention of just the notable products is included in the proposed Corporate overview section below to illustrate the type of products that the company produces. Inkian Jason (talk) 20:55, 1 March 2018 (UTC)

Infobox requests
Hello! I am back with an additional edit request, which I am submitting on behalf of Allergan as part of my work at Beutler Ink. For this request, I propose three specific updates to the article's infobox:


 * 1) Changing the "Industry" field to simply "": "" are too specific and seem more appropriate for a products/services field. Allergan offers other pharmaceutical services and devices, so "Healthcare" is more encompassing. Not to mention, the current "Products" field already says "Branded and generic pharmaceuticals", which seems redundant.
 * 2) Changing the "Founder" field: Currently, the infobox displays, "" I propose including "", per this source, which says, "Gavin Herbert founded Allergan Inc. above his father’s drugstore in 1948. The company is now known as Allergan Plc, with international headquarters in Dublin and $15 billion in annual revenue." Should the founders of both Actavis and Allergan Inc. be included? I seek input from volunteer editors about how to best approach this.
 * 3) Updating the financial parameters and number of employees: Currently, the "Revenue" parameter displays 2016 information. I propose using this same source to display 2016 information for the other parameters, too. This would mean changing the "net income" field to "", the "total assets" field to "", and the "total equity" field to "" (see pg. 48). If we're continuing with 2016 details, the "number of employees" field can be updated from "" to "" (see pg. 22).

I will have additional requests for updating and improving this article, but this request is enough for volunteer editors to review for now. Please let me know if you have any questions. Thank you! Inkian Jason (talk) 21:38, 1 February 2018 (UTC)

Reply 1-FEB-2018
✅
 * 1) The industry title remains, as their primary focus in heathcare is therapeutics.
 * 2) Gavin Herbert founded Allergan, Inc. and had nothing to do with Allergan, which formed just recently. They share only the name, not the legacy.
 * 3) Certain financials were updated; others, such as operating income, were not.
 * 4) Employee number was updated.


 * Regards,  Spintendo  ᔦᔭ   00:13, 2 February 2018 (UTC)
 * Thank you for your help, User:Spintendo, and for updating the infobox. The relationship between Actavis, Allergan Inc. and Allergan PLC (the subject of this article) is definitely not the clearest it could be in this article. I'm working with my contact to understand that better and hopefully offer some more updates soon. Meantime, please note that that the entries for Allen Chao and David Hsia are currently unsourced, and their names do not appear elsewhere in the article's prose. Furthermore, Allen Chao's Wikipedia article does not mention Allergan or Actavis. I hope you'll reconsider removing their names from the infobox. Inkian Jason (talk) 21:07, 2 February 2018 (UTC)
 * ✅  Spintendo  ᔦᔭ   02:20, 3 February 2018 (UTC)
 * Thank you. One quick correction to your changes: The employee number statistic is for 2016, not June 2015. Do you mind making this correction? Inkian Jason (talk) 20:03, 5 February 2018 (UTC)
 * Another editor corrected the date with this edit. Inkian Jason (talk) 16:17, 15 February 2018 (UTC)

Proposed "Corporate overview" section
I am back with an additional request, which I am submitting on behalf of Allergan as part of my work at Beutler Ink.

Currently, this article jumps straight into a complicated, six-sectioned corporate history. I think the article could benefit from starting with a "Corporate overview" section, providing a snapshot of the company before diving right into history details. Based on similar overview sections for company articles, I propose the following, which includes mention of the company's formation, headquarters (and second major operations hub), the number of employees and revenue for 2016, the name of the current chief executive, and a brief summary of Allergan's products and business model:

Allergan was created in 2015 when the company formerly known as Actavis, Plc acquired Allergan, Inc. and continued to use Allergan's name. Allergan is based in Dublin and has major operations in Irvine. In 2016, the company had 16,700 employees and earned $14.57 billion. Brent Saunders serves as Allergan's chief executive officer (CEO).

In 2015, prior to Teva Pharmaceutical Industries' purchase of the company's generic drugs business, Allergan offered approximately 1,000 products, including branded generics, over-the-counter drugs, and generic forms of popular pharmaceutical drugs. Since the sale of Allergan Generics, the company has focused on branded pharmaceuticals. Some of the company's products include: Avycaz, Botox CoolSculpting, Dalvance, Juvéderm, Linzess, Viberzi, and Vraylar.

==Corporate overview== Allergan was created in 2015 when the company formerly known as Actavis, Plc acquired Allergan, Inc. and continued to use Allergan's name. Allergan is based in Dublin and has major operations in Irvine. In 2016, the company had 16,700 employees and earned $14.57 billion. Brent Saunders serves as Allergan's chief executive officer (CEO).

In 2015, prior to Teva Pharmaceutical Industries' purchase of the company's generic drugs business, Allergan offered approximately 1,000 products, including branded generics, over-the-counter drugs, and generic forms of popular pharmaceutical drugs. Since the sale of Allergan Generics, the company has focused on branded pharmaceuticals. Some of the company's products include: Avycaz, Botox CoolSculpting, Dalvance, Juvéderm, Linzess, Viberzi, and Vraylar.

I don't think these claims are very controversial to include, not to mention they help verify some of the (currently unsourced) content displayed in the article's infobox. Note: The SEC citation included in the rendering and markup above, which I included for easier editor review, is already used in the article. In order to avoid duplication, I suggest naming the SEC source and re-calling this citation within the proposed overview section.

I will not be editing the article directly given my conflict of interest, and I'm seeking help from neutral editors to review and implement this content appropriately. I see you have made quite a few contributions to the article in the past, and have an interest in biotech and pharmaceutical companies. Would you consider taking a look at this proposed article improvement? I can address questions or concerns here, and thanks for any help in advance. Inkian Jason (talk) 17:01, 6 February 2018 (UTC)


 * thanks for the tag, I will read this today/tomorrow and reply. Thanks XyZAn (talk) 18:05, 6 February 2018 (UTC)
 * Great, thank you. Let me know if you have any questions. Inkian Jason (talk) 17:29, 12 February 2018 (UTC)


 * Hi again, I wanted to update and ping this request since I noticed that some problematic edits (as well as some helpful ones) have been made to the article within the last day (diff1 and diff2). Given these edits, I'd like to propose the following changes:


 * Removing the recent History addition, and reverting back to the previous Corporate history section
 * Reverting back to the previous version of the introduction, without the list of products
 * Removing the listed owners in the infobox, since the company is publicly traded, and re-adding the previously existing (but poorly formatted) Ownership section


 * As well, I've taken this opportunity to revisit my proposed Corporate overview and have made a few adjustments, including removing products lacking Wikipedia articles (Botox Cosmetic/Vistabel, Botox Therapeutic, Lo Loestrin Fe, and Ozurdex), in order to keep focus on the most notable products. Wanted to make sure you'd seen these recent edits and my update here in case you're still working on reviewing my request. Thanks, Inkian Jason (talk) 20:52, 1 March 2018 (UTC)

Move to Allergan plc
The formal name of Allergan is Allergan plc, which I propose this article title should be moved to. Allergan plc is the title the SEC gives Allergan on their 10=K, and also legally connects Allergan to being an Irish company (which it is). It also avoids confusion with the older Allergan, Inc. etc. Britishfinance (talk)